X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Celecoxib,Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: E-58425
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Kowa Pharmaceuticals America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2021
Details:
Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rimegepant Sulfate
Therapeutic Area: Neurology Product Name: Nurtec ODT
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sodium Oligomannate
Therapeutic Area: Neurology Product Name: GV-971
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s or Parkinson’s disease.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
